UZLeuven
Welcome,         Profile    Billing    Logout  
 97 Trials 
51 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vergote, Ignace B
INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed
3
540
Europe, Canada, US, RoW
NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol
NovoCure Ltd.
Ovarian Cancer
05/23
05/23
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting
2
48
Europe
Atezolizumab, Doxorubicin
Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG
Cervical Cancer
09/25
09/25
Dubois, Christophe LF
HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Recruiting
N/A
30
Europe, RoW
CLARITY
HighLife SAS
Mitral Regurgitation
12/25
02/31
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Recruiting
N/A
120
Europe, RoW
HighLife Transcatheter Mitral Valve Replacement
HighLife SAS, ICON plc
Mitral Regurgitation
03/25
06/30
RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting
N/A
200
Europe, RoW
Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)
Abbott Medical Devices
Mitral Valve Regurgitation
05/25
05/29
Sinnaeve, Peter R
STREAM-2, NCT02777580 / 2016-001642-26: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Completed
4
609
Europe, Canada, RoW
Tenecteplase, TNKase, Metalyse, Clopidogrel, Coronary angiography, Primary PCI
KU Leuven, Boehringer Ingelheim, Life Sciences Research Partners, Fund for Clinical Cardiovascular Research at LRD
Myocardial Infarction
10/22
09/23
NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated
N/A
28
Europe, RoW
Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention
Ceric Sàrl, Abbott
Out of Hospital Cardiac Arrest
01/23
01/23
Vansteenkiste, Johan
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
Gillard, Pieter
RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Active, not recruiting
N/A
200
Europe
Omnipod 5 System
Insulet Corporation
Diabetes Mellitus, Type 1
08/24
08/25
Adriaenssens, Tom
NCT04591938: FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Recruiting
N/A
50
Europe
Fantom Encore Bioresorbable scaffold implantation
Joost Daemen, Horizon 2020 - European Commission, REVA Medical, Inc.
Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence
06/21
12/25
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed
N/A
307
Europe
Optical Coherence Tomography (OCT)
University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT
In-stent Restenosis
12/22
12/22
casteels, kristina m
NCT06452654: Anti-viral Action Against Type 1 Diabetes Autoimmunity

Recruiting
4
2252
Europe
Comirnaty Injectable Product, Comirnaty 3µg/dose for children for 6 month - 4 years, Sodium Chloride 0.9% Inj, Solution for Injection
Technical University of Munich, Helmholtz Zentrum München, University Hospital Carl Gustav Carus, Kinderkrankenhaus auf der Bult, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Newcastle-upon-Tyne Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Birmingham Women's and Children's NHS Foundation Trust
Diabetes Mellitus, Type 1
10/27
10/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting
3
15
Europe
Metreleptin
Amryt Pharma
Generalized Lipodystrophy
09/26
09/26
SINT1A, NCT04769037: Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

Active, not recruiting
N/A
1149
Europe
B. infantis, Placebo
Helmholtz Zentrum München, Technical University of Munich, Kinderkrankenhaus auf der Bult, University Hospital Carl Gustav Carus, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Medical University of Warsaw, Cambridge Biomedical Campus, Cambridge, UK, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Diabetes Mellitus, Type 1
10/27
10/27
Braly, Patricia
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting
2
53
Europe, Canada, US
Nirogacestat, PF-03084014
SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
07/26
12/27
Gerven, Laura H Van
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry

Recruiting
N/A
4550
Europe
Change Accelerator in Respiratory Care
Chronic Rhinosinusitis (Diagnosis)
06/25
12/25
SPAT_AI, NCT05918354: Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies

Completed
N/A
993
Europe
Skin Prick Automated Test
Hippocreates
Allergy
09/24
09/24
Tack, Jan
MOVE-IT, NCT05621811 / 2021-002254-86: Different Doses of Naronapride Vs. Placebo in Gastroparesis

Recruiting
2
320
Europe, US
Naronapride, Placebo
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Gastroparesis
09/25
12/25
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
OCARINA, NCT05740631 / 2020-004180-13: The Effect of Obeticholic Acid in Healthy Volunteers

Recruiting
N/A
12
Europe
Ocaliva, obeticholic acid, Placebo, Placebo Oral Tablet (Starch)
Universitaire Ziekenhuizen KU Leuven, Intercept Pharmaceuticals
Healthy
07/23
07/23
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Recruiting
N/A
130
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
12/24
12/24
Stalmans, Ingeborg
BelGlaucoma, NCT05703724: Prevalence of Glaucoma in Belgium: a Multicenter National Trial

Completed
N/A
1418
Europe
AI algorithm for the detection of glaucoma
Universitaire Ziekenhuizen KU Leuven, Santen Oy
Glaucoma
05/23
05/23
Tomassetti, Carla
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Morlion, Bart
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24
Bennett, Johan
OCTOBER, NCT03171311: The Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction

Active, not recruiting
N/A
1201
Europe
Angiographic guided PCI, PCI, percutaneous transluminal coronary angioplasty (PTCA), OCT guided PCI, OCT
Aarhus University Hospital Skejby, Abbott
Ischaemic Heart Disease, Ischemic Heart Disease
03/22
05/29
PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Active, not recruiting
N/A
60
Europe
LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)
Elixir Medical Corporation
Coronary Artery Disease
04/24
09/24
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Tejpar, Sabine
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
AZUR-4, NCT06567782: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Not yet recruiting
2
120
Europe
Dostarlimab, GSK4057190A, TSR-042, CAPEOX
GlaxoSmithKline
Neoplasms, Colon
09/28
09/28
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting
2
70
Europe
Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
09/25
12/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

Recruiting
N/A
936
Europe
Comprehensive genomic profiling
The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx
Solid Tumor, Metastatic Cancer
05/23
05/26
Goffin, Karolien
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
Claessen, Guido
ENDURE, NCT05731466: Exercise Right Ventricular Coupling in HFpEF

Recruiting
N/A
30
Europe
CardioMems HF System, CMR
Universitaire Ziekenhuizen KU Leuven, Abbott
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
10/24
12/25
Wauters, Els
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
Bouberhan, Sara
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting
1
240
Europe, Canada, Japan, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors, Neoplasms
10/26
07/27
DEKERVEL, Jeroen
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
Herpe, Filip Van
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
Devresse, Arnaud
MARIBEL, NCT06677892: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Recruiting
N/A
75
Europe
No Intervention
Takeda
Cytomegalovirus (CMV)
08/26
09/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vergote, Ignace B
INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed
3
540
Europe, Canada, US, RoW
NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol
NovoCure Ltd.
Ovarian Cancer
05/23
05/23
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting
2
48
Europe
Atezolizumab, Doxorubicin
Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG
Cervical Cancer
09/25
09/25
Dubois, Christophe LF
HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Recruiting
N/A
30
Europe, RoW
CLARITY
HighLife SAS
Mitral Regurgitation
12/25
02/31
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Recruiting
N/A
120
Europe, RoW
HighLife Transcatheter Mitral Valve Replacement
HighLife SAS, ICON plc
Mitral Regurgitation
03/25
06/30
RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting
N/A
200
Europe, RoW
Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)
Abbott Medical Devices
Mitral Valve Regurgitation
05/25
05/29
Sinnaeve, Peter R
STREAM-2, NCT02777580 / 2016-001642-26: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Completed
4
609
Europe, Canada, RoW
Tenecteplase, TNKase, Metalyse, Clopidogrel, Coronary angiography, Primary PCI
KU Leuven, Boehringer Ingelheim, Life Sciences Research Partners, Fund for Clinical Cardiovascular Research at LRD
Myocardial Infarction
10/22
09/23
NCT04431661: CAOCT: Intra CoronAry Optical Computerized Tomography in out-of Hospital Cardiac Arrest Patients

Terminated
N/A
28
Europe, RoW
Optical Coherence Tomography, Coronary Angiography, Per cutaneous coronary intervention
Ceric Sàrl, Abbott
Out of Hospital Cardiac Arrest
01/23
01/23
Vansteenkiste, Johan
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
Gillard, Pieter
RADIANT, NCT05923827: Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

Active, not recruiting
N/A
200
Europe
Omnipod 5 System
Insulet Corporation
Diabetes Mellitus, Type 1
08/24
08/25
Adriaenssens, Tom
NCT04591938: FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Recruiting
N/A
50
Europe
Fantom Encore Bioresorbable scaffold implantation
Joost Daemen, Horizon 2020 - European Commission, REVA Medical, Inc.
Percutaneous Coronary Intervention, Myocardial Revascularization, Tomography, Optical Coherence
06/21
12/25
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed
N/A
307
Europe
Optical Coherence Tomography (OCT)
University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT
In-stent Restenosis
12/22
12/22
casteels, kristina m
NCT06452654: Anti-viral Action Against Type 1 Diabetes Autoimmunity

Recruiting
4
2252
Europe
Comirnaty Injectable Product, Comirnaty 3µg/dose for children for 6 month - 4 years, Sodium Chloride 0.9% Inj, Solution for Injection
Technical University of Munich, Helmholtz Zentrum München, University Hospital Carl Gustav Carus, Kinderkrankenhaus auf der Bult, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Newcastle-upon-Tyne Hospitals NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Birmingham Women's and Children's NHS Foundation Trust
Diabetes Mellitus, Type 1
10/27
10/27
NCT06502990: Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting
3
15
Europe
Metreleptin
Amryt Pharma
Generalized Lipodystrophy
09/26
09/26
SINT1A, NCT04769037: Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

Active, not recruiting
N/A
1149
Europe
B. infantis, Placebo
Helmholtz Zentrum München, Technical University of Munich, Kinderkrankenhaus auf der Bult, University Hospital Carl Gustav Carus, Skane University Hospital, Universitaire Ziekenhuizen KU Leuven, Medical University of Warsaw, Cambridge Biomedical Campus, Cambridge, UK, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Diabetes Mellitus, Type 1
10/27
10/27
Braly, Patricia
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors

Active, not recruiting
2
53
Europe, Canada, US
Nirogacestat, PF-03084014
SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
07/26
12/27
Gerven, Laura H Van
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry

Recruiting
N/A
4550
Europe
Change Accelerator in Respiratory Care
Chronic Rhinosinusitis (Diagnosis)
06/25
12/25
SPAT_AI, NCT05918354: Development and Evaluation of an Artificial Intelligence Model for the Diagnosis of Aeroallergies

Completed
N/A
993
Europe
Skin Prick Automated Test
Hippocreates
Allergy
09/24
09/24
Tack, Jan
MOVE-IT, NCT05621811 / 2021-002254-86: Different Doses of Naronapride Vs. Placebo in Gastroparesis

Recruiting
2
320
Europe, US
Naronapride, Placebo
Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH
Gastroparesis
09/25
12/25
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
OCARINA, NCT05740631 / 2020-004180-13: The Effect of Obeticholic Acid in Healthy Volunteers

Recruiting
N/A
12
Europe
Ocaliva, obeticholic acid, Placebo, Placebo Oral Tablet (Starch)
Universitaire Ziekenhuizen KU Leuven, Intercept Pharmaceuticals
Healthy
07/23
07/23
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Recruiting
N/A
130
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
12/24
12/24
Stalmans, Ingeborg
BelGlaucoma, NCT05703724: Prevalence of Glaucoma in Belgium: a Multicenter National Trial

Completed
N/A
1418
Europe
AI algorithm for the detection of glaucoma
Universitaire Ziekenhuizen KU Leuven, Santen Oy
Glaucoma
05/23
05/23
Tomassetti, Carla
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Active, not recruiting
2
380
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Morlion, Bart
NCT04429919 / 2019-003502-28: AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Completed
2
99
Europe, RoW
AP-325, Placebo
Algiax Pharmaceuticals GmbH, FGK Clinical Research GmbH
Peripheral Post-surgical Neuropathic Pain
10/24
10/24
Bennett, Johan
OCTOBER, NCT03171311: The Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction

Active, not recruiting
N/A
1201
Europe
Angiographic guided PCI, PCI, percutaneous transluminal coronary angioplasty (PTCA), OCT guided PCI, OCT
Aarhus University Hospital Skejby, Abbott
Ischaemic Heart Disease, Ischemic Heart Disease
03/22
05/29
PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Active, not recruiting
N/A
60
Europe
LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)
Elixir Medical Corporation
Coronary Artery Disease
04/24
09/24
BALI, NCT04253171: Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Active, not recruiting
N/A
200
Europe
Lithoplasty, Shockwave, Lithotripsy, Conventional
Herlev and Gentofte Hospital, Abbott, Shockwave Medical, Inc.
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
09/24
01/25
Tejpar, Sabine
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
AZUR-4, NCT06567782: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Not yet recruiting
2
120
Europe
Dostarlimab, GSK4057190A, TSR-042, CAPEOX
GlaxoSmithKline
Neoplasms, Colon
09/28
09/28
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting
2
70
Europe
Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
09/25
12/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

Recruiting
N/A
936
Europe
Comprehensive genomic profiling
The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx
Solid Tumor, Metastatic Cancer
05/23
05/26
Goffin, Karolien
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed
3
300
Europe, Canada, US, RoW
89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)
Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd
Clear Cell Renal Cell Carcinoma
10/22
11/22
Claessen, Guido
ENDURE, NCT05731466: Exercise Right Ventricular Coupling in HFpEF

Recruiting
N/A
30
Europe
CardioMems HF System, CMR
Universitaire Ziekenhuizen KU Leuven, Abbott
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
10/24
12/25
Wauters, Els
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
05/25
02/26
Bouberhan, Sara
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
BEHOLD-1, NCT06431594: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

Recruiting
1
240
Europe, Canada, Japan, US, RoW
GSK5733584
GlaxoSmithKline
Solid Tumors, Neoplasms
10/26
07/27
DEKERVEL, Jeroen
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
Herpe, Filip Van
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
Devresse, Arnaud
MARIBEL, NCT06677892: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

Recruiting
N/A
75
Europe
No Intervention
Takeda
Cytomegalovirus (CMV)
08/26
09/26

Download Options